Delving into the Latest Updates on Cyproterone Acetate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CyPat, Cyproterone 17-O-acetate, Cyproterone acetate (JAN/USAN)

+ [6]

Target

AR

Mechanism

AR antagonists(Androgen Receptor antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic Cancer

Inactive Indication

Hot Flashes

Originator Organization

Bayer AG

Active Organization

Bayer Australia Ltd.

Inactive Organization

Barr Laboratories, Inc.

Drug Highest PhaseApproved

First Approval Date

AU (30 Aug 2007),

Prostatic Cancer

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC24H29ClO4

InChIKeyUWFYSQMTEOIJJG-FDTZYFLXSA-N

CAS Registry427-51-0

AbstractContextThe plasma metabolome is a functional readout of metabolic activity and is associated with phenotypes exhibiting sexual dimorphism, such as cardiovascular disease. Sex hormones are thought to play a key role in driving sexual dimorphism.ObjectiveGender-affirming hormone therapy (GAHT) is a cornerstone of transgender care, but longitudinal changes in the plasma metabolome with feminizing GAHT have not been described.MethodsBlood samples were collected at baseline and after 3 and 6 months of GAHT from transgender women (n = 53). Participants were randomized to different anti-androgens, cyproterone acetate or spironolactone. Nuclear magnetic resonance-based metabolomics was used to measure 249 metabolic biomarkers in plasma. Additionally, we used metabolic biomarker data from an unrelated cohort of children and their parents (n = 3748) to identify sex- and age-related metabolite patterns.ResultsWe identified 43 metabolic biomarkers altered after 6 months in both anti-androgen groups, most belonging to the very low- or low-density lipoprotein subclasses, with all but 1 showing a decrease. We observed a cyproterone acetate-specific decrease in glutamine, glycine, and alanine levels. Notably, of the metabolic biomarkers exhibiting the most abundant “sex- and age-related” pattern (higher in assigned female children and lower in assigned female adults, relative to assigned males), 80% were significantly lowered after GAHT, reflecting a shift toward the adult female profile.ConclusionOur results suggest an anti-atherogenic signature in the plasma metabolome after the first 6 months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.

01 Oct 2024·Transgender Health

Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study” by Yaish et al.

Article

Author: Ruggles, Tomi ; Cheung, Ada S.

01 Oct 2024·Transgender Health

Response to Ruggles and Cheung, Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study”

Article

Author: Sofer, Yael ; Greenman, Yona ; Yaish, Iris ; Tordjman, Karen M.

1

News (Medical) associated with Cyproterone Acetate

16 Jul 2019

·www.bioportfolio.com

Canada: National Pharmacare Or ‘Fill The Gaps’?

A national pharmacare program in Canada could make it harder to access higher cost drugs. Related Stories ‘UK Waiver’ For SPCs Proposed In Case Of No-Deal Brexit EMA Reviews Meningioma Risk With Cyproterone Medicines NICE Overcomes UK Reimbursement Doubts Over Forxiga, US FDA Says No To Approval

100 Deals associated with Cyproterone Acetate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01368	Cyproterone Acetate	G03HA01	DB04839

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	AU	Bayer Australia Ltd.	30 Aug 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hot Flashes	Discovery	US	Barr Laboratories, Inc.	01 Dec 1999
Prostatic Cancer	Discovery	US	Barr Laboratories, Inc.	01 Dec 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2016	Not Applicable	-	27	Cyproterone Acetate (CA)	(ttnauethrb) = became more unfavourable during CA, but restored with addition of E txgkvdacyl (suzgwallmv ) View more	-	10 Sep 2016
				Cyproterone Acetate + Estrogens (CA+E)
ESPE2014	Not Applicable	Fibrous Dysplasia, Polyostotic \| Puberty, Precocious	-	Ketoconazole	aquejwktsm(ycysbgvskx) = khjsueopvw npyuxgbibe (jxwnfuvkpj )	-	18 Sep 2014
				Cyproterone Acetate	aquejwktsm(ycysbgvskx) = qdaeofpxjj npyuxgbibe (jxwnfuvkpj )